CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T, Tulkens D, Van Nieuwenhuysen T, Przybyl J, Demuynck S, van de Rijn M, Al-Jazrawe M, Alman BA, Coucke PJ, De Leeneer K, Vanhove C, Savvides SN, Creytens D, Vleminckx K.
Naert T, et al. Among authors: przybyl j.
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2115116118. doi: 10.1073/pnas.2115116118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34789568
Free PMC article.